Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALNY

Alnylam Pharmaceuticals Inc

Mar 13 • 04:00PM ET

241.75

Dollar change -0.68
Percentage change -0.28	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BMRN BIIB IONS SRPT ARWR NTLA CRSP EDIT

| Held by: VTI VO VXF VUG VOT IBB IWP XBI VHT IWR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.17	Insider Own	4.42%	Shs Outstand	129.29M	Perf Week	-2.57%
Market Cap	31.30B	Forward P/E	205.54	EPS next Y	1.18	Insider Trans	-1.76%	Shs Float	123.73M	Perf Month	-10.13%
Income	-278.16M	PEG	-	EPS next Q	-0.93	Inst Own	95.48%	Short Float	2.02%	Perf Quarter	-5.53%
Sales	2.25B	P/S	13.92	EPS this Y	26.92%	Inst Trans	-0.30%	Short Ratio	3.60	Perf Half Y	-5.64%
Book/sh	0.52	P/B	465.91	EPS next Y	173.82%	ROA	-6.84%	Short Interest	2.49M	Perf Year	62.14%
Cash/sh	20.81	P/C	11.61	EPS next 5Y	-	ROE	-	52W Range	141.98 - 304.39	Perf YTD	2.74%
Dividend Est.	-	P/FCF	-	EPS past 5Y	23.11%	ROI	-10.47%	52W High	-20.58%	Beta	0.35
Dividend TTM	-	Quick Ratio	2.71	Sales past 5Y	63.53%	Gross Margin	85.62%	52W Low	70.28%	ATR (14)	9.13
Dividend Ex-Date	-	Current Ratio	2.78	EPS Y/Y TTM	38.54%	Oper. Margin	-7.87%	RSI (14)	42.94	Volatility	3.94% 3.76%
Employees	2230	Debt/Eq	40.89	Sales Y/Y TTM	22.97%	Profit Margin	-12.37%	Recom	1.85	Target Price	309.59
Option/Short	Yes / Yes	LT Debt/Eq	38.58	EPS Q/Q	40.90%	Payout	-	Rel Volume	0.69	Prev Close	242.43
Sales Surprise	1.81%	EPS Surprise	-9.78%	Sales Q/Q	34.90%	Earnings	Feb 13 BMO	Avg Volume	691.73K	Price	241.75
SMA20	-1.92%	SMA50	-4.91%	SMA200	-3.02%	Trades		Volume	475,333	Change	-0.28%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-12-24	Downgrade	Wolfe Research	Peer Perform → Underperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-16-24	Upgrade	Goldman	Neutral → Buy	$198 → $370
Feb-16-24	Downgrade	Goldman	Buy → Neutral	$173
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-08-23	Initiated	Wells Fargo	Equal Weight	$171
Dec-08-23	Initiated	Wells Fargo	Equal Weight
Oct-11-23	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-23	Initiated	Raymond James	Outperform	$208
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$200 → $250
Apr-26-23	Initiated	SMBC Nikko	Neutral	$220
Mar-21-23	Initiated	Bernstein	Outperform	$243
Jan-18-23	Initiated	Canaccord Genuity	Buy	$310
Sep-09-22	Resumed	Morgan Stanley	Equal-Weight	$222
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral	$175
Jun-27-22	Downgrade	Guggenheim	Buy → Neutral
Jun-07-22	Initiated	William Blair	Outperform
Apr-25-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$210 → $178
Mar-01-22	Initiated	Citigroup	Buy	$223
Feb-03-22	Upgrade	Guggenheim	Neutral → Buy	$170

Show Previous Ratings

Mar-11-25 08:00AM	Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum (Business Wire)
Mar-05-25 07:00AM	Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary (Business Wire)
Feb-27-25 01:30PM	Q4 2024 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-25-25 07:00AM	Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day (Business Wire)
Feb-24-25 07:11PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
12:59PM	Loading…
12:59PM	Alnylam Pharmaceuticals (ALNY): Among the Oversold Biotech Stocks to Buy Now (Insider Monkey)
Feb-14-25 04:35PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
02:10AM	Alnylam Pharmaceuticals Inc (ALNY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Feb-13-25 11:26PM	Q4 2024 Alnylam Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
09:30AM	Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
09:15AM	Alnylam Pharmaceuticals (ALNY) Beats Q4 Earnings and Revenue Estimates (Zacks)
08:18AM	Alnylam: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress (Business Wire)
Feb-10-25 09:16AM	Ahead of Alnylam (ALNY) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
Feb-06-25 10:01AM	Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
08:00AM	Loading…
Jan-30-25 08:00AM	Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Jan-23-25 09:50AM	Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum Stock (Zacks)
Jan-21-25 07:20PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) +7.60%
09:40AM	Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? (Zacks)
Jan-12-25 04:00PM	Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals (Business Wire)
Jan-06-25 08:00AM	Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-25-24 09:40AM	Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-23-24 10:09AM	Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Performing Biotech Stock in 2024? (Insider Monkey)
Dec-04-24 12:00PM	What Makes Alnylam (ALNY) a New Buy Stock (Zacks)
Dec-02-24 02:48PM	Why Is Alnylam Pharmaceuticals, Inc. (ALNY) Among the Best High Growth Healthcare Stocks to Invest In Now? (Insider Monkey)
Nov-27-24 07:00AM	Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference (Business Wire)
05:38AM	Kronos, Idorsia plan layoffs; PTC shelves ALS drug (BioPharma Dive)
Nov-25-24 04:16PM	BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug (Investor's Business Daily)
07:00AM	Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy (Business Wire)
Nov-22-24 02:16PM	BridgeBio heart drug approved by FDA, setting up battle with Pfizer (BioPharma Dive)
07:24AM	Loading…
Nov-18-24 07:24AM	Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment (Clinical Trials Arena)
Nov-17-24 09:30AM	Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose (Business Wire)
Nov-15-24 07:19PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) -8.67%
Nov-06-24 12:26PM	Top 20 biopharmas market cap rises 2% in Q3 2024 amid flurry of drug approvals (Pharmaceutical Technology)
04:27AM	An RNAi renaissance is creating a new generation of startups (BioPharma Dive)
Nov-04-24 08:00AM	Alnylam to Webcast Presentations at Upcoming November Investor Conferences (Business Wire)
Nov-01-24 10:34AM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
03:05AM	Alnylam Pharmaceuticals Inc (ALNY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
01:11AM	Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight (GuruFocus.com)
12:25AM	Q3 2024 Alnylam Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Oct-31-24 10:00AM	Alnylam (ALNY) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks) -5.29%
09:10AM	Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:07AM	Alnylam: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity (Business Wire)
Oct-30-24 11:31AM	Cognizant signs deal to enhance Alnylams IT infrastructure (Verdict)
08:00AM	Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024 (Business Wire)
Oct-28-24 09:16AM	Seeking Clues to Alnylam (ALNY) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Oct-24-24 10:01AM	Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-23-24 12:00PM	Alnylam Pharmaceuticals (ALNY) is a Great Momentum Stock: Should You Buy? (Zacks)
Oct-17-24 09:40AM	Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? (Zacks)
08:00AM	Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results (Business Wire)
Oct-16-24 08:00AM	Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy (Business Wire)
Oct-09-24 12:14PM	Biotech Eyes Early Entry As Several Factors Could Unleash Shares (Investor's Business Daily)
07:00AM	Protein prediction wins chemistry Nobel; Alnylam submits an all-important drug application (BioPharma Dive)
07:00AM	Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy (Business Wire)
Oct-08-24 07:41AM	Startup led by John Maraganore raises $135M to build future of RNAi (BioPharma Dive)
Oct-07-24 03:00AM	Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney (BioPharma Dive)
Oct-01-24 09:40AM	Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:03AM	Not Holding Alnylam Pharmaceuticals (ALNY) Hurt Fidelity Growth Strategies Funds Performance (Insider Monkey)
Sep-29-24 09:00AM	Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 (Business Wire)
Sep-26-24 08:00AM	Alnylam to Webcast TTR Investor Day (Business Wire)
Sep-14-24 07:03PM	Alnylam Pharmaceuticals, Inc. (ALNY): Hedge Funds Are Bullish on This Aggressive Growth Stock (Insider Monkey)
Sep-13-24 07:10PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Sep-12-24 01:01PM	The Brawl Taking Shape Over Pfizers Multibillion-Dollar Heart Monopoly (The Wall Street Journal)
Sep-08-24 02:01AM	Alnylam Pharmaceuticals, Inc. (ALNY): Do Hedge Funds Recommend This Biotech Stock Now? (Insider Monkey)
Sep-06-24 07:09PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Aug-30-24 04:19PM	Why IBD 50's Alnylam Just Reversed Its 50% Gain And BridgeBio Surged (Investor's Business Daily) -8.47%
04:03PM	Alnylam Stock Falls on Positive but Disappointing Study Results for Heart Drug (The Wall Street Journal)
02:33PM	ESC Congress: Amvuttra data signals positive prospects in cardiomyopathy for Alnylam (Pharmaceutical Technology)
02:33PM	ESC 2024: Amvuttra data signals positive prospects in cardiomyopathy for Alnylam (Pharmaceutical Technology)
10:13AM	Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations (Investor's Business Daily)
06:00AM	Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran? in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress (Business Wire)
02:00AM	Full study data back Alnylam heart drugs benefit, but leave doctors with tough choices (BioPharma Dive)
Aug-28-24 04:00PM	Alnylam to Webcast Presentations at Upcoming September Investor Conferences (Business Wire)
Aug-23-24 10:22AM	Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition (Zacks)
Aug-21-24 02:45AM	Here's Why Alnylam Pharmaceuticals (ALNY) Surged in Q2 (Insider Monkey)
Aug-07-24 09:00AM	The 3 Best Gene Editing Stocks to Buy in August 2024 (InvestorPlace)
08:00AM	Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024 (Business Wire)
Aug-04-24 06:55PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Aug-02-24 09:45AM	Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues (Zacks)
06:39AM	Vir retreats from infectious disease; Vertex shelves AATD drugs (BioPharma Dive)
01:03AM	Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight (GuruFocus.com)
Aug-01-24 07:25PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) +13.12%
11:30AM	Alnylam (ALNY) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
09:15AM	Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates (Zacks)
08:14AM	Alnylam: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity (Business Wire)
Jul-30-24 09:15AM	Seeking Clues to Alnylam (ALNY) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Jul-25-24 10:01AM	Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-18-24 08:00AM	Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results (Business Wire)
06:05AM	Alnylam Stock Is a Blockbuster Biopharma In the Making (InvestorPlace)
Jul-11-24 06:30AM	35% Surge Just the Beginning? Alnylam's Stock Poised for Massive Gains on Heart Drug Success. (InvestorPlace)
Jul-09-24 06:00AM	7 Cheap Biotech Stocks With Major Upside Potential (InvestorPlace)
Jul-08-24 04:52AM	Pipeline Moves: Alnylams Amvuttra approval prospects up after Phase III win (Clinical Trials Arena)
Jul-05-24 03:01PM	Baillie Gifford's Strategic Reduction in Alnylam Pharmaceuticals Holdings (GuruFocus.com)
Jun-25-24 07:45PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) +7.74%
08:59AM	Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals (Zacks)
Jun-24-24 09:41PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) +34.52%
04:11PM	Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug (Investor's Business Daily)
01:54PM	Alnylam Soars on Positive Heart-Drug Data (The Wall Street Journal)

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 03 '25	Sale	243.73	1,911	465,772	14,345	Mar 05 04:22 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 04 '25	Sale	241.15	844	203,532	13,501	Mar 05 04:22 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Mar 03 '25	Sale	243.78	471	114,820	28,011	Mar 05 04:22 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 03 '25	Sale	243.79	1,749	426,384	25,350	Mar 05 04:21 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 04 '25	Sale	241.05	808	194,766	24,542	Mar 05 04:21 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Mar 03 '25	Sale	243.78	1,264	308,141	47,751	Mar 05 04:21 PM
Greenstreet Yvonne	Chief Executive Officer	Mar 03 '25	Sale	243.79	3,877	945,165	98,635	Mar 05 04:20 PM
Fitzgerald Kevin Joseph	Officer	Mar 04 '25	Proposed Sale	241.09	844	203,479		Mar 04 04:07 PM
Garg Pushkal	Officer	Mar 04 '25	Proposed Sale	241.09	808	194,801		Mar 04 04:06 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 27 '25	Option Exercise	0.00	5,921	0	87,447	Mar 03 04:32 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 28 '25	Sale	241.69	2,900	700,894	84,547	Mar 03 04:32 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 27 '25	Option Exercise	0.00	1,908	0	34,694	Mar 03 04:31 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 28 '25	Sale	241.70	796	192,390	33,898	Mar 03 04:31 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 27 '25	Option Exercise	0.00	1,667	0	14,858	Mar 03 04:31 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 28 '25	Sale	241.68	513	123,983	14,345	Mar 03 04:31 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 27 '25	Option Exercise	0.00	1,908	0	13,897	Mar 03 04:31 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 28 '25	Sale	241.69	935	225,977	12,962	Mar 03 04:31 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 28 '25	Sale	241.69	496	119,878	12,385	Mar 03 04:30 PM
Garg Pushkal	Officer	Mar 03 '25	Proposed Sale	246.18	973	239,533		Mar 03 04:09 PM
Fitzgerald Kevin Joseph	Officer	Mar 03 '25	Proposed Sale	246.18	1,171	288,277		Mar 03 04:09 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 14 '25	Sale	255.17	1,213	309,527	81,526	Feb 18 04:49 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 14 '25	Sale	255.17	967	246,750	32,786	Feb 18 04:47 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 18 '25	Sale	251.56	1,440	362,243	12,881	Feb 18 04:47 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 14 '25	Sale	255.21	663	169,204	14,321	Feb 18 04:47 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 14 '25	Sale	255.17	1,561	398,325	13,537	Feb 18 04:47 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 18 '25	Sale	251.67	1,548	389,579	11,989	Feb 18 04:47 PM
Garg Pushkal	Officer	Feb 18 '25	Proposed Sale	256.95	1,548	397,759		Feb 18 04:14 PM
Fitzgerald Kevin Joseph	Officer	Feb 18 '25	Proposed Sale	256.95	1,440	370,008		Feb 18 04:13 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Jan 27 '25	Option Exercise	88.95	48,876	4,347,520	64,581	Jan 29 04:03 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Jan 27 '25	Sale	285.00	52,592	14,988,720	11,989	Jan 29 04:03 PM
Garg Pushkal	Officer	Jan 27 '25	Proposed Sale	285.00	52,592	14,988,720		Jan 27 04:01 PM
SHARP PHILLIP A	Director	Jan 23 '25	Option Exercise	131.21	11,250	1,476,112	11,250	Jan 24 04:10 PM
SHARP PHILLIP A	Director	Jan 23 '25	Sale	275.00	11,250	3,093,750	0	Jan 24 04:10 PM
SHARP PHILLIP A	Director	Jan 23 '25	Proposed Sale	275.00	11,250	3,093,750		Jan 23 04:17 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Dec 12 '24	Sale	251.00	1,752	439,760	15,705	Dec 13 04:13 PM
Garg Pushkal	Officer	Dec 12 '24	Proposed Sale	255.02	1,752	446,795		Dec 12 04:05 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 26 '24	Sale	250.98	5,219	1,309,853	78,880	Nov 27 05:22 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Nov 26 '24	Sale	250.98	1,682	422,144	17,457	Nov 27 05:22 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Nov 26 '24	Sale	250.98	1,682	422,144	30,644	Nov 27 05:21 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Nov 26 '24	Sale	250.98	1,469	368,686	13,191	Nov 27 05:21 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 27 '24	Sale	252.29	1,531	386,261	12,881	Nov 27 05:20 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 26 '24	Sale	250.98	1,469	368,686	14,412	Nov 27 05:20 PM
Fitzgerald Kevin Joseph	Officer	Nov 27 '24	Proposed Sale	253.98	1,531	388,843		Nov 27 04:06 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 20 '24	Option Exercise	85.00	15,000	1,275,000	88,441	Aug 22 08:01 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 20 '24	Sale	280.00	15,000	4,200,000	73,441	Aug 22 08:01 PM
Greenstreet Yvonne	Officer	Aug 20 '24	Proposed Sale	280.00	15,000	4,200,000		Aug 20 05:10 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Aug 12 '24	Option Exercise	89.09	20,725	1,846,429	34,906	Aug 14 04:12 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Aug 12 '24	Sale	270.99	22,025	5,968,516	12,881	Aug 14 04:12 PM
Fitzgerald Kevin Joseph	Officer	Aug 12 '24	Proposed Sale	269.52	22,025	5,936,178		Aug 12 04:07 PM
Ausiello Dennis A	Director	Aug 06 '24	Option Exercise	119.68	20,250	2,423,452	20,386	Aug 08 04:10 PM
Ausiello Dennis A	Director	Aug 06 '24	Sale	262.00	20,250	5,305,586	136	Aug 08 04:10 PM
Ausiello Dennis A	Director	Aug 06 '24	Proposed Sale	266.66	20,250	5,399,865		Aug 06 04:07 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 01 '24	Option Exercise	85.00	15,148	1,287,580	88,589	Aug 02 08:01 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 01 '24	Sale	270.00	15,148	4,089,960	73,441	Aug 02 08:01 PM
Greenstreet Yvonne	Officer	Aug 01 '24	Proposed Sale	270.00	15,148	4,089,960		Aug 01 04:01 PM
Greenstreet Yvonne	Chief Executive Officer	Jul 11 '24	Sale	261.00	7,093	1,851,273	73,441	Jul 12 08:02 PM
SCHULMAN AMY W	Director	Jun 25 '24	Option Exercise	131.21	8,500	1,115,285	16,936	Jun 27 04:04 PM
SCHULMAN AMY W	Director	Jun 25 '24	Sale	240.00	8,500	2,040,000	8,436	Jun 27 04:04 PM
PYOTT DAVID E I	Director	Jun 24 '24	Option Exercise	80.76	32,450	2,620,611	32,586	Jun 26 04:28 PM
PYOTT DAVID E I	Director	Jun 24 '24	Sale	220.69	32,450	7,161,360	136	Jun 26 04:28 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Jun 25 '24	Sale	230.99	2,103	485,773	15,609	Jun 26 04:28 PM
Greenstreet Yvonne	Chief Executive Officer	Jun 25 '24	Sale	230.99	8,301	1,917,475	80,534	Jun 26 04:27 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Jun 25 '24	Sale	231.00	1,605	370,747	28,892	Jun 26 04:26 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Jun 25 '24	Sale	231.00	1,605	370,747	11,660	Jun 26 04:26 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Jun 25 '24	Sale	230.99	1,198	276,731	14,181	Jun 26 04:26 PM
SCHULMAN AMY W	Director	May 29 '24	Option Exercise	66.83	30,000	2,004,900	30,136	May 31 07:00 PM
SCHULMAN AMY W	Director	May 29 '24	Sale	148.60	21,700	3,224,546	8,436	May 31 07:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALNY

Alnylam Pharmaceuticals Inc

Upgrade your FINVIZ experience